Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Resilience

Biotech & Life Sciences · San Diego, United States · Founded 2020 Unicorn

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation
$2.5–5B
Latest valuation · 2026
Unlock exact value
Revenue
$500M–1B
Latest reported FY
Unlock exact value
Headcount
1–2k
Current team size
Unlock exact value

Broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption

Investors

6 investors on Resilience's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series A 1 investor entered at this stage

Global footprint

Where Resilience has talent and traffic

AI talent share
0.5% of workforce is AI talent
(6 of 1,300 staff)
Core AI30.23%
Other AI30.23%
Non-AI workforce1,29499.54%
Workforce by country
6 countries with
team presence
🇺🇸 United States80.8%
🇨🇦 Canada18.3%
🇦🇪 United Arab Emirates0.2%
🇮🇳 India0.2%
🇬🇧 United Kingdom0.1%
Top 5 of 6 shown
Web traffic by country
25K monthly visits
across markets
🇺🇸 United States70%
🇨🇦 Canada13.6%
🇮🇳 India6%
🇬🇧 United Kingdom5.6%
🇳🇱 Netherlands2%
Top 5 markets shown

Patent intelligence

$108M patent portfolio · 50 active families

Estimated portfolio value
$108M
2.9% of valuation · 1.5× the top peer Natera ($71M)
50 active patent families
Where Resilience innovates CellMolecular biologyCancer researchCell lysatesCell biology

Where Resilience concentrates vs peers

Each axis is a top-10 topic across Resilience and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Resilience's 5 investments and acquisitions.

Every disclosed deal where Resilience appeared as a backer or acquirer, 2021–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

5 deals across Resilience's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Resilience deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Resilience's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        5 of 5 deals

        Sentiment on X

        What X is saying about Resilience

        An AI-synthesized read of the highest-engagement posts about Resilience on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Resilience on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.